NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023
Aldafermin demonstrated statistically significant reductions in serum 7αC4 and fecal bile acids versus placebo in patients with idiopathic BAM with IBS-DAround 25-50% of patients with... | May 8, 2023
United States Davidj Woodhouse Exchange Commission Biopharmaceuticals Inc Digestive Disease Week Mayo Clinic
Source: marketscreener.com